U.S. flag An official website of the United States government
  1. Home
  2. Drug Databases
  3. Orange Book Home

Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations

Home | Back to Search Results

Product Details for NDA 021453

Expand all

ZERIT XR (STAVUDINE)
37.5MG
Marketing Status: Discontinued
Active Ingredient: STAVUDINE
Proprietary Name: ZERIT XR
Dosage Form; Route of Administration: CAPSULE, EXTENDED RELEASE; ORAL
Strength: 37.5MG
Reference Listed Drug: No
Reference Standard: No
TE Code: 
Application Number: N021453
Product Number: 001
Approval Date: Dec 31, 2002
Applicant Holder Full Name: BRISTOL MYERS SQUIBB CO
Marketing Status:  Discontinued
Patent and Exclusivity Information
ZERIT XR (STAVUDINE)
50MG
Marketing Status: Discontinued
Active Ingredient: STAVUDINE
Proprietary Name: ZERIT XR
Dosage Form; Route of Administration: CAPSULE, EXTENDED RELEASE; ORAL
Strength: 50MG
Reference Listed Drug: No
Reference Standard: No
TE Code: 
Application Number: N021453
Product Number: 002
Approval Date: Dec 31, 2002
Applicant Holder Full Name: BRISTOL MYERS SQUIBB CO
Marketing Status:  Discontinued
Patent and Exclusivity Information
ZERIT XR (STAVUDINE)
75MG
Marketing Status: Discontinued
Active Ingredient: STAVUDINE
Proprietary Name: ZERIT XR
Dosage Form; Route of Administration: CAPSULE, EXTENDED RELEASE; ORAL
Strength: 75MG
Reference Listed Drug: No
Reference Standard: No
TE Code: 
Application Number: N021453
Product Number: 003
Approval Date: Dec 31, 2002
Applicant Holder Full Name: BRISTOL MYERS SQUIBB CO
Marketing Status:  Discontinued
Patent and Exclusivity Information
ZERIT XR (STAVUDINE)
100MG
Marketing Status: Discontinued
Active Ingredient: STAVUDINE
Proprietary Name: ZERIT XR
Dosage Form; Route of Administration: CAPSULE, EXTENDED RELEASE; ORAL
Strength: 100MG
Reference Listed Drug: No
Reference Standard: No
TE Code: 
Application Number: N021453
Product Number: 004
Approval Date: Dec 31, 2002
Applicant Holder Full Name: BRISTOL MYERS SQUIBB CO
Marketing Status:  Discontinued
Patent and Exclusivity Information
Back to Top